FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200416086> ?p ?o ?g. }

• W4200416086 endingPage "114086" @default.
• W4200416086 startingPage "114086" @default.
• W4200416086 abstract "Many pyrimidine-based xanthine oxidase (XO) inhibitors with diverse chemotypes have been reported recently. Our previous study revealed that 2-(4-alkoxy-3-cyano)phenyl-6-imino-1,6-dihydropyrimidine-5-carboxylic acid derivatives exhibited remarkable XO inhibitory potency. Notably, an intramolecular hydrogen bond (IMHB) formed between amino and carboxylic groups could be observed. With the hope to expand the structure-activity relationships (SARs) and obtain potential pyrimidine-based XO inhibitors, IMHB interruption and scaffold hopping were carried out on these compounds to design 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids (11a-11n and 15a-15j) and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones (19a-19j). Among them, compound 19a (IC50 = 0.039 μM) was identified as the most promising compound with substantially higher in vitro inhibitory potency than allopurinol (IC50 = 7.590 μM) and comparable to febuxostat (IC50 = 0.028 μM). The SAR analysis revealed that interrupting the IMHB through the removal of the amino group could damage the XO inhibitory potency; pyrimidine-4-carboxylic acid moiety was more beneficial for the XO inhibitory potency than the pyrimidine-5-carboxylic acid moiety. Additionally, enzyme kinetics studies suggested that compounds 11a, 15a and 19a acted as mixed-type inhibitors for XO and the removal of 6-position amino group resulted in a weakened affinity to the free enzyme, but an enhanced binding to the enzyme-substrate complex. Molecular modeling provided a reasonable explanation for the SARs observed in this study. Furthermore, in vivo hypouricemic effects demonstrated that compounds 15a and 19a could effectively reduce serum uric acid levels at an oral dose of 10 mg/kg, with 19a demonstrating a stronger effect than 15a. Therefore, our study proved that 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones were potent pyrimidine-based XO inhibitors and compound 19a required further structural optimization as a potential and efficacious agents for the treatment of hyperuricemia and gout." @default.
• W4200416086 created "2021-12-31" @default.
• W4200416086 creator A5036462261 @default.
• W4200416086 creator A5045007031 @default.
• W4200416086 creator A5045473616 @default.
• W4200416086 creator A5070050402 @default.
• W4200416086 creator A5072594467 @default.
• W4200416086 creator A5078003697 @default.
• W4200416086 creator A5080226615 @default.
• W4200416086 date "2022-02-01" @default.
• W4200416086 modified "2023-09-27" @default.
• W4200416086 title "Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors" @default.
• W4200416086 cites W1232052622 @default.
• W4200416086 cites W1936992143 @default.
• W4200416086 cites W2010727971 @default.
• W4200416086 cites W2014279267 @default.
• W4200416086 cites W2023156261 @default.
• W4200416086 cites W2038247534 @default.
• W4200416086 cites W2067300585 @default.
• W4200416086 cites W2083852489 @default.
• W4200416086 cites W2084918245 @default.
• W4200416086 cites W2284186025 @default.
• W4200416086 cites W2565095705 @default.
• W4200416086 cites W2590989864 @default.
• W4200416086 cites W2594851071 @default.
• W4200416086 cites W2606140748 @default.
• W4200416086 cites W2733852024 @default.
• W4200416086 cites W2745975919 @default.
• W4200416086 cites W2751843656 @default.
• W4200416086 cites W2793103574 @default.
• W4200416086 cites W2806836891 @default.
• W4200416086 cites W2900220652 @default.
• W4200416086 cites W2912340640 @default.
• W4200416086 cites W2914927315 @default.
• W4200416086 cites W2938806944 @default.
• W4200416086 cites W2951178388 @default.
• W4200416086 cites W2963392551 @default.
• W4200416086 cites W2963763020 @default.
• W4200416086 cites W2996021244 @default.
• W4200416086 cites W2998185788 @default.
• W4200416086 cites W3027931819 @default.
• W4200416086 cites W3036764923 @default.
• W4200416086 cites W3106493990 @default.
• W4200416086 cites W3148510320 @default.
• W4200416086 cites W3182618419 @default.
• W4200416086 cites W3205198139 @default.
• W4200416086 doi "https://doi.org/10.1016/j.ejmech.2021.114086" @default.
• W4200416086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34992040" @default.
• W4200416086 hasPublicationYear "2022" @default.
• W4200416086 type Work @default.
• W4200416086 citedByCount "3" @default.
• W4200416086 countsByYear W42004160862023 @default.
• W4200416086 crossrefType "journal-article" @default.
• W4200416086 hasAuthorship W4200416086A5036462261 @default.
• W4200416086 hasAuthorship W4200416086A5045007031 @default.
• W4200416086 hasAuthorship W4200416086A5045473616 @default.
• W4200416086 hasAuthorship W4200416086A5070050402 @default.
• W4200416086 hasAuthorship W4200416086A5072594467 @default.
• W4200416086 hasAuthorship W4200416086A5078003697 @default.
• W4200416086 hasAuthorship W4200416086A5080226615 @default.
• W4200416086 hasConcept C112887158 @default.
• W4200416086 hasConcept C178790620 @default.
• W4200416086 hasConcept C185592680 @default.
• W4200416086 hasConcept C2776568683 @default.
• W4200416086 hasConcept C2779074116 @default.
• W4200416086 hasConcept C2779321679 @default.
• W4200416086 hasConcept C2780263894 @default.
• W4200416086 hasConcept C32909587 @default.
• W4200416086 hasConcept C55493867 @default.
• W4200416086 hasConcept C71240020 @default.
• W4200416086 hasConcept C90150868 @default.
• W4200416086 hasConceptScore W4200416086C112887158 @default.
• W4200416086 hasConceptScore W4200416086C178790620 @default.
• W4200416086 hasConceptScore W4200416086C185592680 @default.
• W4200416086 hasConceptScore W4200416086C2776568683 @default.
• W4200416086 hasConceptScore W4200416086C2779074116 @default.
• W4200416086 hasConceptScore W4200416086C2779321679 @default.
• W4200416086 hasConceptScore W4200416086C2780263894 @default.
• W4200416086 hasConceptScore W4200416086C32909587 @default.
• W4200416086 hasConceptScore W4200416086C55493867 @default.
• W4200416086 hasConceptScore W4200416086C71240020 @default.
• W4200416086 hasConceptScore W4200416086C90150868 @default.
• W4200416086 hasFunder F4320321001 @default.
• W4200416086 hasLocation W42004160861 @default.
• W4200416086 hasLocation W42004160862 @default.
• W4200416086 hasOpenAccess W4200416086 @default.
• W4200416086 hasPrimaryLocation W42004160861 @default.
• W4200416086 hasRelatedWork W1966534378 @default.
• W4200416086 hasRelatedWork W1970805202 @default.
• W4200416086 hasRelatedWork W1984013527 @default.
• W4200416086 hasRelatedWork W2007560269 @default.
• W4200416086 hasRelatedWork W2044091401 @default.
• W4200416086 hasRelatedWork W2078849089 @default.
• W4200416086 hasRelatedWork W2113582953 @default.
• W4200416086 hasRelatedWork W2314328420 @default.
• W4200416086 hasRelatedWork W2591086070 @default.
• W4200416086 hasRelatedWork W2762216252 @default.
• W4200416086 hasVolume "229" @default.

• next